Academic Journal
أعرض في EDS

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.

التفاصيل البيبلوغرافية
العنوان: ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
المؤلفون: Soo, R.A., Dafni, U., Han, J.Y., Cho, B.C., Nadal, E., Yeo, C.M., Carcereny, E., de Castro, J., Sala, M.A., Coate, L., Provencio, M., Britschgi, C., Vagenknecht, P., Dimopoulou, G., Kammler, R., Finn, S.P., Peters, S., Stahel, R.A.
المساهمون: ETOP 10-16 BOOSTER Collaborators
المصدر: Clinical cancer research, vol. 30, no. 22, pp. 5180-5191
سنة النشر: 2024
المجموعة: Université de Lausanne (UNIL): Serval - Serveur académique lausannois
مصطلحات موضوعية: Humans, Aniline Compounds/therapeutic use, Aniline Compounds/administration & dosage, Acrylamides/therapeutic use, Female, Drug Resistance, Neoplasm/genetics, Male, Circulating Tumor DNA/genetics, Circulating Tumor DNA/blood, Middle Aged, Aged, ErbB Receptors/genetics, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bevacizumab/therapeutic use, Bevacizumab/administration & dosage, Mutation, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Adult, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/genetics, Non-Small-Cell Lung/pathology, Non-Small-Cell Lung/mortality, 80 and over, High-Throughput Nucleotide Sequencing
الوصف: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described. A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively. The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm.
نوع الوثيقة: article in journal/newspaper
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/39250635; info:eu-repo/semantics/altIdentifier/eissn/1557-3265; https://serval.unil.ch/notice/serval:BIB_CD5E14800EE8
DOI: 10.1158/1078-0432.CCR-24-0932
الاتاحة: https://serval.unil.ch/notice/serval:BIB_CD5E14800EE8
https://doi.org/10.1158/1078-0432.CCR-24-0932
رقم الانضمام: edsbas.C5078BDB
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.C5078BDB
925
3
Academic Journal
academicJournal
925.377258300781
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.C5078BDB&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://serval.unil.ch/notice/serval:BIB_CD5E14800EE8# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Soo%2C+R%2EA%2E%22">Soo, R.A.</searchLink><br /><searchLink fieldCode="AR" term="%22Dafni%2C+U%2E%22">Dafni, U.</searchLink><br /><searchLink fieldCode="AR" term="%22Han%2C+J%2EY%2E%22">Han, J.Y.</searchLink><br /><searchLink fieldCode="AR" term="%22Cho%2C+B%2EC%2E%22">Cho, B.C.</searchLink><br /><searchLink fieldCode="AR" term="%22Nadal%2C+E%2E%22">Nadal, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Yeo%2C+C%2EM%2E%22">Yeo, C.M.</searchLink><br /><searchLink fieldCode="AR" term="%22Carcereny%2C+E%2E%22">Carcereny, E.</searchLink><br /><searchLink fieldCode="AR" term="%22de+Castro%2C+J%2E%22">de Castro, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Sala%2C+M%2EA%2E%22">Sala, M.A.</searchLink><br /><searchLink fieldCode="AR" term="%22Coate%2C+L%2E%22">Coate, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Provencio%2C+M%2E%22">Provencio, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Britschgi%2C+C%2E%22">Britschgi, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Vagenknecht%2C+P%2E%22">Vagenknecht, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Dimopoulou%2C+G%2E%22">Dimopoulou, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Kammler%2C+R%2E%22">Kammler, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Finn%2C+S%2EP%2E%22">Finn, S.P.</searchLink><br /><searchLink fieldCode="AR" term="%22Peters%2C+S%2E%22">Peters, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Stahel%2C+R%2EA%2E%22">Stahel, R.A.</searchLink> )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => ETOP 10-16 BOOSTER Collaborators )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Clinical cancer research, vol. 30, no. 22, pp. 5180-5191 )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2024 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Université de Lausanne (UNIL): Serval - Serveur académique lausannois )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Aniline+Compounds%2Ftherapeutic+use%22">Aniline Compounds/therapeutic use</searchLink><br /><searchLink fieldCode="DE" term="%22Aniline+Compounds%2Fadministration+%26+dosage%22">Aniline Compounds/administration & dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Acrylamides%2Ftherapeutic+use%22">Acrylamides/therapeutic use</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Resistance%22">Drug Resistance</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasm%2Fgenetics%22">Neoplasm/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Circulating+Tumor+DNA%2Fgenetics%22">Circulating Tumor DNA/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Circulating+Tumor+DNA%2Fblood%22">Circulating Tumor DNA/blood</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22ErbB+Receptors%2Fgenetics%22">ErbB Receptors/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22">Antineoplastic Combined Chemotherapy Protocols/therapeutic use</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fadverse+effects%22">Antineoplastic Combined Chemotherapy Protocols/adverse effects</searchLink><br /><searchLink fieldCode="DE" term="%22Bevacizumab%2Ftherapeutic+use%22">Bevacizumab/therapeutic use</searchLink><br /><searchLink fieldCode="DE" term="%22Bevacizumab%2Fadministration+%26+dosage%22">Bevacizumab/administration & dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Mutation%22">Mutation</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%2Fdrug+therapy%22">Lung Neoplasms/drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%2Fgenetics%22">Lung Neoplasms/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%2Fpathology%22">Lung Neoplasms/pathology</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%2Fmortality%22">Lung Neoplasms/mortality</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%22">Carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung%2Fdrug+therapy%22">Non-Small-Cell Lung/drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung%2Fgenetics%22">Non-Small-Cell Lung/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung%2Fpathology%22">Non-Small-Cell Lung/pathology</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung%2Fmortality%22">Non-Small-Cell Lung/mortality</searchLink><br /><searchLink fieldCode="DE" term="%2280+and+over%22">80 and over</searchLink><br /><searchLink fieldCode="DE" term="%22High-Throughput+Nucleotide+Sequencing%22">High-Throughput Nucleotide Sequencing</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described. A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively. The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/39250635; info:eu-repo/semantics/altIdentifier/eissn/1557-3265; https://serval.unil.ch/notice/serval:BIB_CD5E14800EE8 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1158/1078-0432.CCR-24-0932 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://serval.unil.ch/notice/serval:BIB_CD5E14800EE8<br />https://doi.org/10.1158/1078-0432.CCR-24-0932 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.C5078BDB )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1158/1078-0432.CCR-24-0932 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Humans [Type] => general ) [1] => Array ( [SubjectFull] => Aniline Compounds/therapeutic use [Type] => general ) [2] => Array ( [SubjectFull] => Aniline Compounds/administration & dosage [Type] => general ) [3] => Array ( [SubjectFull] => Acrylamides/therapeutic use [Type] => general ) [4] => Array ( [SubjectFull] => Female [Type] => general ) [5] => Array ( [SubjectFull] => Drug Resistance [Type] => general ) [6] => Array ( [SubjectFull] => Neoplasm/genetics [Type] => general ) [7] => Array ( [SubjectFull] => Male [Type] => general ) [8] => Array ( [SubjectFull] => Circulating Tumor DNA/genetics [Type] => general ) [9] => Array ( [SubjectFull] => Circulating Tumor DNA/blood [Type] => general ) [10] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [11] => Array ( [SubjectFull] => Aged [Type] => general ) [12] => Array ( [SubjectFull] => ErbB Receptors/genetics [Type] => general ) [13] => Array ( [SubjectFull] => Antineoplastic Combined Chemotherapy Protocols/therapeutic use [Type] => general ) [14] => Array ( [SubjectFull] => Antineoplastic Combined Chemotherapy Protocols/adverse effects [Type] => general ) [15] => Array ( [SubjectFull] => Bevacizumab/therapeutic use [Type] => general ) [16] => Array ( [SubjectFull] => Bevacizumab/administration & dosage [Type] => general ) [17] => Array ( [SubjectFull] => Mutation [Type] => general ) [18] => Array ( [SubjectFull] => Lung Neoplasms/drug therapy [Type] => general ) [19] => Array ( [SubjectFull] => Lung Neoplasms/genetics [Type] => general ) [20] => Array ( [SubjectFull] => Lung Neoplasms/pathology [Type] => general ) [21] => Array ( [SubjectFull] => Lung Neoplasms/mortality [Type] => general ) [22] => Array ( [SubjectFull] => Adult [Type] => general ) [23] => Array ( [SubjectFull] => Carcinoma [Type] => general ) [24] => Array ( [SubjectFull] => Non-Small-Cell Lung/drug therapy [Type] => general ) [25] => Array ( [SubjectFull] => Non-Small-Cell Lung/genetics [Type] => general ) [26] => Array ( [SubjectFull] => Non-Small-Cell Lung/pathology [Type] => general ) [27] => Array ( [SubjectFull] => Non-Small-Cell Lung/mortality [Type] => general ) [28] => Array ( [SubjectFull] => 80 and over [Type] => general ) [29] => Array ( [SubjectFull] => High-Throughput Nucleotide Sequencing [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Soo, R.A. ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dafni, U. ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Han, J.Y. ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Cho, B.C. ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nadal, E. ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yeo, C.M. ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Carcereny, E. ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => de Castro, J. ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sala, M.A. ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Coate, L. ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Provencio, M. ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Britschgi, C. ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Vagenknecht, P. ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dimopoulou, G. ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kammler, R. ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Finn, S.P. ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Peters, S. ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Stahel, R.A. ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => ETOP 10-16 BOOSTER Collaborators ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2024 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Clinical cancer research, vol. 30, no. 22, pp. 5180-5191 [Type] => main ) ) ) ) ) ) )
IllustrationInfo